Aspire Biopharma Holdings (ASBP) Cash from Operations (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Cash from Operations of 3038522.0 for Q1 2026, down 73.48% year-over-year from 11456763.9 in Q1 2025, and down 227.48% quarter-over-quarter from 927841.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Cash from Operations (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Cash from Operations for 6 consecutive years, with 3038522.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 73.48% year-over-year to 3038522.0; the TTM figure through Mar 2026 stood at 6210482.0 (down 240.53% YoY), while the FY2025 annual figure was 4923488.0, down 1756.62% from the prior year.
- Cash from Operations slipped to 3038522.0 in Q1 2026 per ASBP's latest filing, from 927841.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 479569.0 in Q4 2024 and bottomed at 3038522.0 in Q1 2026.
- Historically, Cash from Operations has averaged 605240.53 across 5 years, with a median of 189951.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations jumped 407.16% — and 2025, when it tumbled 1927.43%.
- Aspire Biopharma Holdings' Cash from Operations stood at 35870.0 in 2022, then plunged by 335.26% to 156128.0 in 2023, then surged by 407.16% to 479569.0 in 2024, then tumbled by 293.47% to 927841.0 in 2025, then plunged by 227.48% to 3038522.0 in 2026.
- Business Quant data shows ASBP's Cash from Operations at 3038522.0 in Q1 2026, 927841.0 in Q4 2025, and 1103809.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | -2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.12 Mn |
| Jun 30, 2026 | -2.12 Mn |
| Mar 31, 2026 | -3.04 Mn |
| Mar 31, 2026 | -3.04 Mn |
| Dec 31, 2025 | -927,841.00 |
| Dec 31, 2025 | -927,841.00 |
| Sep 30, 2025 | -1.10 Mn |
| Sep 30, 2025 | -1.10 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Dec 31, 2024 | 479,569.00 |
| Dec 31, 2024 | 479,569.00 |
| Sep 30, 2024 | -495,540.00 |
| Sep 30, 2024 | -495,540.00 |
| Jun 30, 2024 | -56,244.00 |
| Jun 30, 2024 | -56,244.00 |
| Mar 31, 2024 | -192,971.00 |
| Mar 31, 2024 | -192,971.00 |